Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma

This is a Phase II, single-centre, non-randomized, single-arm clinical trial to investigate the efficacy and safety of neoadjuvant nivolumab therapy in adult participants with resectable, locoregionally advanced Oral Squamous Cell Carcinoma (OSCC) tumors. Identification of predictive molecular biomarkers of tumor response to treatment will also be performed.

NCT Number	NCT07514767
Lead Sponsor	Prof. Lars Olaf Cardell
Conditions	Oral Squamous Cell Carcinoma (OSCC)
Enrollment	60 participants
Start Date	2026-05-01
Primary Completion	2028-09 (estimated)
Study Completion	2033-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-07